Oral Session 3-5A ALL

[OS3-5A-5] Impact of MRD and salvage status on outcomes in a phase 3 trial of inotuzumab ozogamicin for R/R ALL

Elias Jabbour¹, Nicola Gokbuget², Naohito Fujishima³, Anjali Advani⁴, Matthias Stelljes⁵, Wendy Stock⁶, Michaela Liedtke⁷, Giovanni Martinelli⁸, Susan OBrien⁹, Tao Wang¹⁰, A. Douglas Laird¹¹, Erik Vandendries¹², Alexander Neuhof¹³, Daniel J. DeAngelo¹⁴, Hagop Kantarjian¹ (1.University of Texas, MD Anderson Cancer Center, Houston, United States of America, 2.Goethe University, Frankfurt, Federal Republic of Germany, 3.Akita University, Akita, Japan, 4.Cleveland Clinic Taussig Cancer Institute, Cleveland, United States of America, 5.Muenster University Hospital, Muenster, Federal Republic of Germany, 6.University of Chicago, Chicago, United States of America, 7.Stanford Cancer Institute, Stanford, United States of America, 8.Institute Seragnoli, University of Bologna, Bologna, Italian Republic, 9.University of California, Irvine Medical Center, Orange, United States of America, 10.Pfizer, Inc, Groton, United States of America, 11.Pfizer, Inc, San Diego, United States of America, 12.Pfizer, Inc, Cambridge, United States of America, 13.Pfizer Pharma GmbH, Berlin, Federal Republic of Germany, 14.Dana-Farber Cancer Institute, Boston, United States of America)